Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.
Daratumumab
Leukapheresis
Multiple myeloma
Stem cell collection
Thalidomide
Journal
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie
ISSN: 1660-3796
Titre abrégé: Transfus Med Hemother
Pays: Switzerland
ID NLM: 101176417
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
16
11
2022
accepted:
13
02
2023
medline:
8
11
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
epublish
Résumé
In transplant-eligible, newly diagnosed multiple myeloma (NDMM) patients, autologous peripheral blood stem cell (PBSC) collection is usually pursued after induction therapy. While induction regimens are constantly refined regarding response, their impact on PBSC collection is not fully studied. The inclusion of the anti-CD38 antibody daratumumab into induction therapy significantly improved outcomes for patients with NDMM, e.g., as part of the daratumumab, bortezomib, thalidomide, and dexamethasone (Dara-VTD) protocol. Preliminary data from the phase 3 CASSIOPEIA study proved the efficacy of Dara-VTD. While overall PBSC collection upon addition of daratumumab was reduced in the study population, more detailed analyses on the impact are missing. We here report on PBSC mobilization and collection metrics in Patient characteristics were well balanced between groups. The Dara-VTD group showed improved response parameters with 66% of patients reaching at least very good partial response versus 54% in the VCD group. Dara-VTD patients exhibited inferior mobilization metrics such as peripheral blood CD34 In summary, Dara-VTD, possibly due to both anti-CD38 antibody and thalidomide exposure, imposes a limitation on PBSC collection which can be only partly overcome by utilization of plerixafor.
Identifiants
pubmed: 37936633
doi: 10.1159/000529691
pii: tmh-0050-0371
pmc: PMC10626396
doi:
Types de publication
Journal Article
Langues
eng
Pagination
371-381Informations de copyright
Copyright © 2023 by The Author(s). Published by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The first authors and all coauthors confirm that there are no potential conflicts of interest to disclose, except the following. Joseph Kauer: Honoraria: AstraZeneca. Sandra Sauer: travel grants or honoraria for presentations for Celgene, BMS, Janssen, Takeda, and Amgen. Katharina Kriegsmann: research funding and honoraria from Sanofi. A.S. received travel grants from Hexal and Jazz Pharmaceuticals, research grant from Therakos/Mallinckrodt, consultant by Janssen-Cilag and BMS, and is co-founder of TolerogenixX Ltd. A.S. is a part-time employee of TolerogenixX Ltd.
Références
N Engl J Med. 1996 Jul 11;335(2):91-7
pubmed: 8649495
Leukemia. 2007 Jun;21(6):1294-9
pubmed: 17377586
Bone Marrow Transplant. 2001 May;27(9):925-31
pubmed: 11436102
Blood. 2019 Oct 17;134(16):1337-1345
pubmed: 31484647
J Natl Cancer Inst. 2019 Jan 1;111(1):7-8
pubmed: 29897483
Blood. 2020 Aug 20;136(8):936-945
pubmed: 32325490
Leuk Lymphoma. 2019 Sep;60(9):2199-2206
pubmed: 30845862
Blood. 2012 Aug 23;120(8):1589-96
pubmed: 22791289
Ann Oncol. 2021 Mar;32(3):309-322
pubmed: 33549387
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
Leukemia. 2007 Sep;21(9):2035-42
pubmed: 17581613
J Clin Oncol. 2010 Dec 10;28(35):e741-3; author reply e744-5
pubmed: 21060027
Biol Blood Marrow Transplant. 2010 Apr;16(4):490-9
pubmed: 19925876
Biol Blood Marrow Transplant. 2013 Mar;19(3):445-9
pubmed: 23186983
Transfusion. 2015 Feb;55(2):275-83
pubmed: 25117969
Bone Marrow Transplant. 2021 Feb;56(2):395-399
pubmed: 32796951
Leukemia. 2008 Jun;22(6):1282-4
pubmed: 18216870
Transfusion. 2017 Oct;57(10):2366-2372
pubmed: 28681435
Lancet Haematol. 2020 Jun;7(6):e456-e468
pubmed: 32359506
Support Care Cancer. 2013 Sep;21(9):2437-42
pubmed: 23591714
Biol Blood Marrow Transplant. 2013 May;19(5):760-6
pubmed: 23298856
Transplant Cell Ther. 2021 Aug;27(8):661.e1-661.e6
pubmed: 33895403
Eur J Haematol. 2015 Jan;94(1):12-22
pubmed: 24797118
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Transfus Med. 2017 Feb;27(1):36-42
pubmed: 27726235
Bone Marrow Transplant. 2020 Dec;55(12):2254-2260
pubmed: 32447348
Int J Hematol. 2013 Apr;97(4):446-55
pubmed: 23420184
Front Immunol. 2020 Aug 14;11:1771
pubmed: 32922390
Blood. 2009 Jun 4;113(23):5720-6
pubmed: 19363221
Biol Blood Marrow Transplant. 2009 Jun;15(6):718-23
pubmed: 19450756
Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61
pubmed: 28453614
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
N Engl J Med. 2003 Dec 25;349(26):2495-502
pubmed: 14695409
Blood. 2016 May 26;127(21):2569-74
pubmed: 27002117
Transfus Apher Sci. 2009 Aug;41(1):33-7
pubmed: 19540167
Bone Marrow Transplant. 2003 Sep;32(6):587-92
pubmed: 12953131
Chem Immunol. 2000;75:169-88
pubmed: 10851784
Leuk Lymphoma. 2013 Oct;54(10):2200-4
pubmed: 23387937
Oncol Lett. 2012 Jan;3(1):55-60
pubmed: 22740856